Andrographolide has a protective effect on the cardiovascular system. To study its cardic-electrophysiological effects, action potentials and voltage-gated Na + (I Na ), Ca 2+ (I CaL ), and K + (I K1 , I Kr , I to and I Kur ) currents were recorded using whole-cell patch clamp and current clamp techniques. Additionally, the effects of andrographolide on aconitine-induced arrhythmias were assessed on electrocardiograms in vivo. We found that andrographolide shortened action potential duration and reduced maximum upstroke velocity in rabbit left ventricular and left atrial myocytes. Andrographolide attenuated rate-dependence of action potential duration, and reduced or abolished delayed afterdepolarizations and triggered activities induced by isoproterenol (1 μM) and high calcium ([Ca 2+ ] o =3.6 mM) in left ventricular myocytes. Andrographolide also concentration-dependently inhibited I Na and I CaL , but had no effect on I to , I Kur , I K1 , or I Kr in rabbit left ventricular and left atrial myocytes. Andrographolide treatment increased the time and dosage thresholds of aconitine-induced arrhythmias, and reduced arrhythmia incidence and mortality in rabbits. Our results indicate that andrographolide inhibits cellular arrhythmias (delayed afterdepolarizations and triggered activities) and aconitine-induced arrhythmias in vivo, and these effects result from I Na and I CaL inhibition. Andrographolide may be useful as a class I and IV antiarrhythmic therapeutic.
INTRODUCTION
The traditional medical herb, Andrographis paniculata (Burm.f.) Wall. ex Nees, has been used for centuries to treat a variety of diseases in China. Andrographolide, its major bioactive component, has many pharmacological effects, including antitumor [1, 2] , anti-inflammatory [1] [2] [3] [4] , antiviral [2] , anti-hypertension [5] , antioxidant [3, 6, 7] , antihyperglycaemic [2] , hepatoprotective [2, 7] , and cardioprotective properties [5] [6] [7] [8] [9] [10] [11] . Recent studies found that andrographolide protected rat cardiomyocytes against hypoxia/reoxygenation injury by upregulating cellular-reduced glutathione levels and antioxidant enzyme activities [6] . Andrographolide protected mouse hearts from LPS-induced cardiac malfunctions, and thus may prevent myocardial malfunction during sepsis [8] . Because platelet activation is closely linked to coronary heart disease, andrographolide could be used to treat patients with thromboembolic disorders due to its antiplatelet activity [9] [10] [11] .
Andrographolide has been used clinically for many years, and its cardioprotective properties are known. However, its effects on sodium (I Na ), calcium (I CaL ), and potassium channels (I K1 , I Kr , I to , I Kur ), and action potentials (APs) in cardiomyocytes have not been reported. This study explored the effects of andrographolide on the aforementioned ion channels and action potentials (APs) to determine its antiarrhythmic mechanism of action. 
RESULTS

Effects of andrographolide on APs in rabbit left ventricular and left atrial myocytes
In this study, left ventricular myocytes (LVMs) and left atrial myocytes (LAMs) were isolated at the same time and were tested alternately, so comparisons between LVM and LAM electrical activity parameters were reasonable. LVMs ( Figure 1A , left) were larger and wider in size than LAMs (right), and had more intensive transverse striations.
APs were elicited by depolarizing pulses delivered in a width of 4 ms, 1.5-fold above the threshold at a rate of 1 Hz using the current-clamp technique. Figure 1B shows typical LVM (left) and LAM (right) morphology, and the effect of andrographolide on APs in these cells.
Andrographolide shortened action potential duration at 50% repolarization (APD 50 ) and 90% repolarization (APD 90 ), and decreased maximum upstroke velocity (V max ) in a concentration-dependent manner without changing resting membrane potential (RMP) or action potential amplitude (APA) in LVMs or LAMs. The effects of andrographolide on AP parameters were the same for LVMs and LAMs (Table 1) .
Effects of andrographolide on rate-dependent repolarization of APs in LVMs
APs were recorded using depolarizing pulses delivered in a width of 4 ms, 1.5-fold above the threshold at a rate of 1 Hz using the current-clamp technique.
APs were recorded at stimulation frequencies of 0.5, 1, and 2 Hz with or without andrographolide after the AP 
Effects of andrographolide on isoproterenoland high calcium-induced delayed afterdepolarizations and triggered activities
APs were elicited by string stimulation containing 10 pulses at a basic cycle length (BCL) of 300 ms and string stimulation frequency of 0.125 Hz. APs were recorded after stabilization. Isoproterenol (ISO, 1 μM) was added to the external bath solution and the calcium concentration ([Ca   2+ ] o ) was increased to 3.6 mM at the same time. Under control circumstances, there were no delayed afterdepolarizations (DADs) or triggered activities (TAs). In contrast, ISO (1 μM) and high calcium ([Ca   2+ ] o =3.6 mM) induced DADs and TAs in 7/7 LVMs following 10 consecutive pulses at a BCL of 300 ms ( Figure 1E ). The addition of 20 μM andrographolide abolished TAs and markedly reduced or abolished DADs.
Effects of andrographolide on sodium current (I Na ) in LVMs and LAMs I Na was recorded using 300 ms depolarizing voltage steps between -70 mV and +40 mV in 5 mV increments from a holding potential of -90 mV at a rate of 0.5 Hz with the cells perfused with normal bath solution and recorded the current as control group. After currents stabilized, cells were perfused with solution containing andrographolide (1, 5, 10, or 20 μM). When sealing resistance was stable, currents were recorded under different concentrations and different voltages. Results in a single cell ( Figure  2A -2B) and in a group cell ( Figure 2C-2D ) with or without andrographolide in LVMs and LAMs showed that andrographolide decreased I Na in a concentrationdependent manner without shifting the voltage at which I Na amplitude was maximal.
Steady-state inactivation curves for sodium currents in the absence or presence of 20 μM andrographolide were evaluated from a holding potential of -90 mV. A 100 ms conditioning pre-pulse was applied from -100 mV to +40 mV in 5 mV increments followed by 100 ms depolarizing test pulses to -30 mV at a rate of 0.5 Hz to evoke I Na . Figure 2E- 
Effects of andrographolide on L-type calcium current (I CaL ) in LVMs and LAMs
I CaL was recorded using a 300 ms depolarizing pulse from -40 mV to +50 mV in 5 mV increments at a rate of 0.5 Hz with a holding potential of -40 mV. One of the difficulties of studying I CaL is the run-down phenomenon in which the membrane ruptures. Figure 3A shows I CaL current density changes over time after membrane rupture without addition of any drug in LVMs. I CaL tends to stabilize at 7-25 min after membrane rupture. To show that andrographolide inhibition of I CaL was independent of the run-down phenomenon, the drug was added after I CaL peak amplitude stabilized (about 7 min after membrane rupture). The experiment was accomplished within 25 min after membrane rupture to avoid interference by the run-down phenomena. Figure 3C shows typical I CaL current traces from a single LVM cell under control conditions or with 10 μM andrographolide, washout, and 10 μM nifedipine. 10 μM andrographolide inhibited I CaL , and I CaL amplitude recovered progressively after withdrawal of andrographolide (washout). Then, to identify I CaL , current was recorded after addition of 10 μM nifedipine. I CaL was almost completely blocked by 10 μM nifedipine, indicating that the current recorded with the above pulse stimulation was I CaL . These results demonstrated that andrographolide inhibition of I CaL is significant and reversible ( Figure 3B-3C) . The steady-state I CaL inactivation curves with or without 20 μM andrographolide were evaluated from a holding potential of -40 mV. A 2000 ms conditioning pre-pulse was applied from -50 mV to 0 mV in 5 mV increments followed by 300 ms depolarizing test pulses to 0 mV at a rate of 0.5 Hz to evoke I CaL . Figure 4E -4F show typical example for one single cell of LVMs and LAMs, respectively. Figure 4G shows the steady-state Effect of andrographolide on inward rectifying potassium current (I k1 ) in LVMs I K1 was elicited by 400 ms depolarization voltage from -120 mV to +50 mV in 5 mV increments at a rate of 1 Hz with a holding potential of -40 mV. Figure 5A shows typical I K1 current traces from a single cell before and after 40 μM andrographolide treatment. Neither 20 μM nor 40 μM andrographolide affected I K1 ( Figure 5C ).
Effect of andrographolide on rapid delayed rectifier potassium current (I Kr ) in LVMs I Kr was elicited by 3000 ms depolarization voltage from -40 mV to +50 mV in 10 mV increments followed by a 5000 ms repolarization pulse to -40 mV at a rate of 0.1 Hz with a holding potential of -40 mV. Figure 5B shows typical single cell I Kr current traces before and after 40 μM andrographolide application. Neither 10 μM nor 40 μM andrographolide affected I Kr ( Figure 5D ).
Effect of andrographolide on transient outward potassium current (I to ) in LAMs
I to was recorded using a 400 ms depolarization voltage from -40 mV to +50 mV in 10 mV increments Figure 5E shows typical I to current traces from a single cell before and after 40 μM andrographolide application. Neither 20 μM nor 40 μM andrographolide affected I to ( Figure 5F ).
Effect of andrographolide on ultra-rapid delayed rectifier potassium current (I Kur ) in LAMs I Kur was recorded with an 80 ms pre-pulse to +30 mV to inactivate I to , then repolarized to -50 mV, lasting 50 ms, followed by a 150 ms test pulse to +60 mV from -40 mV in 10 mV increments, at a rate of 0.5 Hz with a holding potential of -50 mV. Neither 20 μM nor 40 μM andrographolide affected I Kur ( Figure 5G ).
Effect of andrographolide on aconitine-induced ventricular arrhythmias in rabbits
Ventricular premature contraction (VPC), ventricular tachycardia (VT), and ventricular fibrillation (VF) appeared in all 10 NS group rabbits, and in 10, 7, and 1 of 10 Andro group rabbits, respectively. Andrographolide treatment prior to aconitine increased the time threshold ( Figure 6A ) and aconitine cumulative dosage ( Figure 6B ) required to induce VPC, VT, and VF compared with the NS group. Andrographolide treatment also reduced rabbit mortality ( Figure 6C ) and aconitine-induced ventricular arrhythmia incidence ( Figure 6D-6E) .
DISCUSSION
This study found that andrographolide inhibited I Na and I CaL in LVMs and LAMs in a concentration-dependent manner. Andrographolide (5 and 10 μM) decreased APD 50 , APD 90 , and V max without affecting RMP and APA in these cells. Treatment also shortened APD and attenuated RD of APD in LVMs in a concentration-dependent manner. We found that 20 μM andrographolide attenuated TAs and DADs induced by ISO (1 μM) and high calcium (3.6 mM) in LVMs. Finally, andrographolide had no influence on I K1 and I Kr in LVMs, or I to and I Kur in LAMs. Our results suggest that andrographolide had cardioprotective effects in rabbits with aconitine-induced arrhythmias.
Andrographolide shifted the I Na inactivation curve toward negative membrane potential and accelerated the inactivation process without changing its slope factor. Decreased I Na amplitude and accelerated I Na inactivation indicated that the number of Na + flowing into the cell was reduced. Since the transient sodium current initiates the action potential [12] , increasing the quantity of current passed through the membrane would enhance cell excitability. Thus, andrographolide decreased cell excitability, which suggests its potential use in treatment of arrhythmias caused by enhanced excitability. ] i homeostasis (calcium overload) is closely related to multiple pathological conditions, including arrhythmia [17] , myocardial ischemia/ reperfusion [18] , heart failure [19] , digitalis intoxication [20] , and hypercalcinemia [21] . Andrographolide inhibited I CaL concentration-dependently, and shifted the I CaL inactivation curve toward negative membrane potential by amplifying its V 1/2 and k values. When k was increased, the inactivation process accelerated. I CaL inactivation acceleration and decreased I CaL amplitude indicated that homeostasis, suggesting its potential use as a class IV antiarrhythmic drug.
Andrographolide did not influence rabbit cardiomyocyte RMP, which was consistent with our finding that it had no effect on LVM I K1 . Andrographolide (5 and 10 μM) had no effect on APA, but reduced V max . A V max reduction can decrease cardiomyocyte excitability and slow down the excitement conduction velocity, which is helpful for inhibiting reentrant tachycardia. Since andrographolide had no influence on I K1 , I Kr , I to , or I Kur , andrographolide mainly shortens APD 50 and APD 90 by inhibiting I CaL . In this study, andrographolide not only shortened AP duration, but also decreased the RD of APD concentration-dependently. When RD decreased, the transmural dispersion of repolarization also diminished. Therefore, andrographolide may reduce the transmural repolarization heterogeneity of APD. Enlargement of APD transmural repolarization heterogeneity leads to the occurrence of arrhythmias [22] . Andrographolide reduced RD, indicating that it may reduce the transmural repolarization heterogeneity of APD, thus also inhibiting reentrant arrhythmias. ] i , thereby resulting in DADs and TAs [23] [24] [25] . DAD-mediated TA can increase abnormal autorhythmicity, causing the majority of sudden cardiac deaths during nonischemic heart failure [24, 25] . In this study, 20 μM andrographolide inhibited DADs and TAs evoked by ISO and high calcium. The potential mechanism may be related to andrographolide inhibition of I CaL and I Na to alleviate intracellular Ca 2+ -and Na + -overloading. This study also found that andrographolide has no effect on I K1 , I Kr , I to , and I Kur . Enhanced reverse ratedependence (RRD) of APD caused by drugs that inhibit I Kr is an undesirable response, as it reduces drug efficacy during tachycardia and may promote proarrhythmic activity after tachycardia termination [26, 27] . Andrographolide as a potential antiarrhythmia therapeutic does not induce such side effects.
Finally, in vivo results indicated that andrographolide had cardioprotective effects in rabbits with aconitine-induced arrhythmias. Aconitine binds to voltage-dependent cardiac Na + channels [28, 29] and prolongs their open state, favoring entry of a large quantity of Na + into cytosol. This may be accompanied by Ca 2+ overload via an electrogenic Na + -Ca 2+ exchange (NCX) system, and eventually induces triggered activity [30, 31] . Furthermore, aconitinine can increase I CaL by accelerating the activation process and delaying inactivation process [32, 33] . We found that andrographolide increased the time threshold and cumulative aconitine dosage required to induce VPC, VT, and VF. It also reduced incidences of aconitineinduced VT and VF, as well as mortality in rabbits. These results indicated that andrographolide had the protective effects on aconitine-induced arrhythmias. And this antiarrhythmic effect of andrographolide was related to its inhibition of I Na and I CaL .
To the best of our knowledge, this is the first demonstration about the effects of andrographolide on cardiac myocyte electrophysiologyical properties, and its possible antiarrhythmic mechanisms is related to its inhibitory effects on I Na and I CaL . Our results of this study indicate that andrographolide may be a potential class I and IV antiarrhythmia agent.
MATERIALS AND METHODS
Ethics statement
Use of rabbits in this investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publication no. 85-23, revised 1996) and the Guide for the Care and Use of Laboratory Animals (Hubei Province, China), and was approved by the Institutional Animal Care and Use Committee of Wuhan University of Science and Technology.
Cardiomyocyte isolation
Single cardiac ventricular and atrial myocytes were enzymatically isolated from adult New Zealand white rabbits (1.7-2 kg weight, 24-32 weeks of age, of either sex), as described preciously [34] . Rabbits were provided by the Experimental Animal Center of Wuhan University of Science and Technology. Rabbits were heparinized (2000 U) and anesthetized with ketamine (30 mg/kg, intravenously) and xylazine (7.5 mg/kg, intramuscularly). After the corneal reflex disappeared, rabbits were fixed on their backs to the test stands. Hearts were quickly removed after thoracotomy and put in a petri dish filled with 37°C, oxygen (95% O 2 and 5% CO 2 ) saturated, Ca 2+ -free Tyrode's solution containing (mM): NaCl 135, NaH 2 PO 4 0.33, KCl 5.4, MgCl 2 1.0, HEPES 10, glucose 10 (pH 7.4, adjusted with NaOH) to stop the heartbeat. Fat and connective tissues were removed from the heart. To eliminate residual blood in the heart cavity, the aorta was cannulated and perfused retrogradely using a modified Langendorff apparatus (perfusion pressure 70 cm H 2 O 2 ), then perfused for 5 more min with oxygen saturated, Ca 2+ -free Tyrode's solution (at 37°C). Hearts were then digested for 30 min with the same solution containing enzyme (collagenase type I, 1 g/L) and bovine serum albumin (BSA, 1 g/L) at 37°C. The enzyme-containing solution was pumped at a constant rate using a peristaltic pump, and gas (95% O 2 and 5% CO 2 ) was allowed to pass through this solution. The perfusate was then switched to preheated and oxygen saturated Kraftbrühe (KB) solution 
Aconitine-induced arrhythmias in rabbits
Adult New Zealand white rabbits were randomly divided into two groups (n=10, each): i) Normal saline (NS) group; ii) andrographolide (Andro) group. Rabbits were then anesthetized and fixed on their backs to test stands. Polyethylene tubing was inserted into the ear marginal vein to administer aconitine, NS, and andrographolide. Standard limb lead II electrocardiogram (ECG) was measured using the BL-420F data acquisition and analysis system (Chengdu TaiMeng, Sichuan, China) following subcutaneous penetration of electrodes into four limbs. After 10 min of stabilization, NS (10 ml) was injected into NS group rabbits in 5 min through the ear marginal vein. Five min later, aconitine (2 μg/kg/ min, flow rate: 80 μl/min) was injected using an infusion pump to induce arrhythmias. Andro group rabbits were treated with 10 ml andrographolide (10 mg/kg) in 5 min prior to aconitine (2 μg/kg/min, flow rate: 80 μl/min). ECG recordings were conducted in both groups for 120 min following aconitine administration. The cumulative dosage of aconitine required to induce VPC, VT and VF was calculated. VPC, VT, and VF time thresholds were recorded.
Drugs and solutions
Collagenase type I and CsCl were purchased from Gibco (Invitrogen Co., Paisley, UK). Bovine serum albumin (BSA) and HEPES were obtained from Roche (Basel, Switzerland). L-glutamic acid and taurine were purchased from Wuhan Zhongnan Chemical Reagent Co. (Wuhan, China). E-4031 and chromanol 293B were obtained from Tocris Bioscience (Minneapolis, MN, USA). All other drugs and reagents were purchased from Sigma Aldrich (Saint Louis, MO, USA). Andrographolide was dissolved in methyl alcohol, chromanol 293B in DMSO, and nifedipine in ethyl alcohol. All drugs were dissolved and diluted into the external recording solution immediately before use. Final methyl alcohol, DMSO, and ethyl alcohol concentrations in the test solutions were ≤0.1% to assure no effects on recorded currents. Stock solution of other drugs were prepared in dH 2 O. Drug concentrations refer to that in the external recording solution.
The 
Current recordings
Transmembrane action potentials and ion currents were recorded from isolated myocytes using a patch clamp amplifier (EPC-10, Heka Electronic, Lambrecht, Pfalz, Germany) with a current or voltage clamp technique, respectively. All experiments were performed at 37±0.5°C and bath solutions were bubbled with 95% O 2 and 5% CO 2 . Before patch clamp recording, myocytes were transferred into a recording chamber mounted on an inverted microscope stage (Nikon TE2000-S) and allowed to adhere to the glass bottom of the chamber for 5 min. A motorized micromanipulator (MP285, Sutter, USA) propelled the recording electrode to the chosen cells. Membranes were then sealed and ruptured with negative pressure. Sealing resistance was maintained >1GΩ. A 80% compensation of series resistance was achieved without ringing. Capacitance and series resistances were adjusted to minimize the contribution of the capacitive transients. Patch electrodes were pulled with a two-stage patch pipette puller (PP-830, Narishige Group, Tokyo, Japan) and then fire-polished. Patch electrodes had a resistance of 1.8-2.5 MΩ when filled with pipette solution. Current signals were conducted by the Ag/AgCl electrode and amplified by an EPC-10 amplifier, then filtered at 1.5 kHz, digitized at 10 kHz, and stored on a computer hard disk for analysis.
Data analysis
Applicate FitMaster (v2x32; HEKA) was used for data analysis and SPSS 18.0 for statistical analysis.
Figures were plotted using Origin software (V7.0, OriginLab Co., MA, USA). Summary data were presented as means±SD. Current density was obtained by dividing www.impactjournals.com/oncotarget current amplitude by cell capacitance. Data from steadystate I Na activation and inactivation were fitted to the Boltzmann equation: Y=1/[1+exp(Vm -V 1/2 )/k], where Vm is the membrane potential, V 1/2 the half-activation or half-inactivation potential, and k the slope factor. For steady-state activation curves, Y represents relative conductance. Chord conductance was calculated using the ratio of the current to electromotive force for potential in individual current-voltage relationships. Conductances were normalized to their individual maximal conductance. For steady-state inactivation curves, Y represents relative current (I Na /I Na max; I CaL /I CaL max). Differences between groups were determined using one-way analysis of variance (ANOVA) followed by the Tukey multiple comparison test or Student's paired t-test. P<0.05 was considered statistically significant.
